Related Experiment Videos

Interactions of meropenem, with beta-lactamases, including enzymes with extended-spectrum activity against

R Labia1, A Morand, K Tiwari

  • 1Muséum National d'Histoire Naturelle, CNRS, Paris, France.

Insights

Meropenem and imipenem carbapenems show high resistance to common beta-lactamases. Meropenem also inactivates some enzymes, offering potential advantages against resistant bacteria.

Area of Science:

  • Microbiology
  • Pharmacology
  • Biochemistry

Background:

  • Beta-lactamases are enzymes that confer bacterial resistance to beta-lactam antibiotics.
  • Emergence of extended-spectrum beta-lactamases (ESBLs) and other resistant enzymes poses a significant therapeutic challenge.
  • Carbapenems like meropenem are crucial for treating infections caused by multidrug-resistant bacteria.

Purpose of the Study:

  • To investigate the interaction of meropenem with a panel of beta-lactamases, including novel TEM- and SHV-related enzymes.
  • To compare the stability and activity of meropenem and imipenem against various classes of beta-lactamases.
  • To assess the potential of meropenem to inactivate beta-lactamase enzymes.

Main Methods:

  • Enzyme kinetics studies were performed using purified beta-lactamase enzymes.
  • Hydrolysis assays were conducted to measure the degradation of meropenem, imipenem, third-generation cephalosporins, and cephamycins.
  • Enzyme inactivation experiments were carried out to assess the effect of carbapenems on beta-lactamase activity.

Main Results:

  • Meropenem and imipenem exhibited high stability against TEM, SHV, and OXA beta-lactamases.
  • Both carbapenems were stable against Class C chromosomal cephalosporinases, unlike third-generation cephalosporins and cephamycins.
  • Meropenem demonstrated enzyme inactivation for some Class A beta-lactamases, a property less pronounced with imipenem.

Conclusions:

  • Meropenem and imipenem are highly effective against a broad range of clinically relevant beta-lactamases.
  • Meropenem's ability to inactivate certain beta-lactamases suggests a potential mechanism for overcoming resistance.
  • These findings support the continued use of carbapenems in treating infections caused by bacteria producing diverse beta-lactamases.

Related Concept Videos